Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer

Marwan Al-Hajeili1,2
Asfar S Azmi3
Minsig Choi2
1Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 2Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; 3Department of Pathology, Wayne State University, Detroit, MI, USA

Abstract: Advanced pancreatic adenocarcinoma is a deadly disease and is considered incurable. For the past two decades, gemcitabine remained the major chemotherapeutic drug with modest clinical benefit. Many chemotherapy and targeted agents were combined with gemcitabine but failed to demonstrate improvement in pancreatic cancer (PC) survival. Taxanes (paclitaxel, docetaxel) were introduced in the clinic as anti-microtubule agents and showed activity against PC cells in vitro; however, clinical efficacy was limited. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer. Recently, nab-paclitaxel was tested in a large Phase III clinical trial in combination with gemcitabine for the treatment of advanced PC. The data showed that the addition of nab-paclitaxel improved the response rate (7% in gemcitabine alone versus 23% in combination), progression-free survival (from 3.7 months to 5.5 months), and overall survival from 6.7 months to 8.5 months, compared to single agent gemcitabine. Through this review, we provide the preclinical and clinical progress in the development of nab-paclitaxel for the treatment of metastatic PC.

Keywords: pancreatic adenocarcinoma, nab-paclitaxel, abraxane, gemcitabine

Introduction
Pancreatic adenocarcinoma comprises 3% of estimated new cancer cases each year, with 44,030 new cases and 37,660 deaths expected in 2013. It is the fourth most common cause of cancer mortality in the US.1 Pancreatic cancer (PC) continues to be one of the most aggressive malignancies with a 5-year survival of less than 2%.2 Pancreatic adenocarcinoma can be defined in terms of accumulating genetic mutations in key tumor activator and inhibitor genes such as Kras and myriad of other regulatory molecules.3 Germline mutations in BRCA2, PALB2, CDKN2A, STK11, and PRSSI genes, and Lynch syndrome, is associated with increased risk of PC.4,5 Progression of PC begins with the appearance of the abnormal expression of Pdx1, hedgehog signaling, Kras oncogenes, and aberration of tumor suppressor genes like p16, p53, and SMAD4/DPC4.3-5 These pathways are fed-forward by frequently cited mutations and the aberrant expression of the DNA sequence; epigenetic factors have been implicated through molecular modifications and dysregulation of microRNAs (miRNAs).

For decades, few drugs have been effective in advanced PC.6 Gemcitabine was considered the only available option for this disease with a median survival of 5.4 months.7 Gemcitabine is a pro-drug that enters the cells aided by membrane transporters.8 Once inside, it is phosphorylated by deoxycytidine kinase (dCK) to an active form.9 Both gemcitabine diphosphate (dFdCPT) and gemcitabine triphosphate (dFdCTP) inhibit processes required for DNA synthesis. Nevertheless, a number of studies have shown that pancreatic cells...
become resistant to gemcitabine through various mechanisms. For example, Hong et al showed that a sub-population of cancer stem-like cells (CSCs) was expanded during the acquisition of gemcitabine resistance in pancreatic tumors. After exposure to high-dose gemcitabine, CSCs that are CD44-positive cells reprogrammed and reconstituted the resistant cell population. Most importantly, these cells overexpress the multi-drug resistance markers and among the ABC transporters, the expression of ABCB1 (MDR1) was significantly augmented in these resistant CSCs. Additionally, our group has recently demonstrated that PC cells acquire resistance to gemcitabine through enhanced plasticity or in other words, undergo epithelial–mesenchymal transition in their phenotype.

Many chemotherapeutic agents in combination with gemcitabine and targeted therapies have failed to improve the low survival rate. Clinicians incorporated anti-EGFR (epidermal growth factor receptor) erlotinib in combination with gemcitabine where the combination improved survival by a mere 2 weeks and the doublet was granted US Food and Drug Administration (FDA) approval. Meanwhile, taxane and related compounds that have been recognized to be effective in treating breast and lung cancers were tried in advanced PC as well. Unfortunately, their toxicity parameters were not favorable and clinical efficacy was not promising. Recently, albumin-bound paclitaxel (Abraxane) has demonstrated superior efficacy in combination with gemcitabine, leading to its FDA approval. In this review, we will discuss clinical progress in the treatment of PC with a special focus on the recently approved nab-paclitaxel.

**Taxanes**

Taxane rings are isolated from bark of Yew (Taxus brevifolia and Taxus baccata), and has antimicrotubular activity and inhibits depolymerization. These mitotic-inhibiting agents exert cytotoxic effects against wide ranges of different tumors. Being pleiotropic agents from plant origin, they have poor aqueous solubility, and extraction requires synthetic solvents. For taxotere, polysorbate 80 is used and for paclitaxel, cremophor EL is used, which is composed of castor oil and ethanol. The presence of the cremophor was considered the primary reason for the allergic reaction associated with the administration of paclitaxel. Furthermore, the addition of cremophor limits the dose, bioavailability, and drug concentration in the tumor tissue.

**Taxanes in PC**

Taxanes were studied in advanced PC as a single agent or in combination. Okada et al investigated docetaxel as a first-line therapy for 21 advanced PC chemo-naïve patients. They observed a median overall survival of 118 days (95% confidence interval [CI]: 105–158 days) and no objective response was noted. The main grade 3–4 toxicities were myelosuppression along with anemia, thrombocytopenia, and nausea/vomiting. Docetaxel, administered at 60 mg/m², did not show significant anti-tumor activity in patients with metastatic PC.

In another study, Androulakis et al demonstrated the efficacy of docetaxel as a first-line agent for 33 advanced PC patients (with performance status 0–1), and found an overall survival of 36 weeks. In this case, docetaxel was administered at 100 mg/m², along with granulocyte colony-stimulating factor on day 2 throughout day 10 every 3 weeks. Although docetaxel demonstrated a marginal objective activity, modest clinical benefit was noted. In a similar fashion, Rougier et al demonstrated the median overall survival to be 7 months in 40 patients with locally advanced and metastatic PC. The incidence and severity of adverse events were similar to other docetaxel studies.

The combination of docetaxel and gemcitabine was studied in chemo-naïve PC patients. Ryan et al demonstrated the efficacy of the combination (docetaxel administered at 60 mg/m² and gemcitabine at 600 mg/m²) in 33 patients (performance status of 0–1) and found a median overall survival of 8.9 months (95% CI: 5.2–11.2 months). The objective response rate was 18%, and the 1-year survival rate was 29%. Stathopoulos et al investigated gemcitabine at 1,000 mg/m² and docetaxel at 100 mg/m² in 54 patients with metastatic PC and found the median survival to be 26 weeks. All these trials had a limited number of patients, with survival ranging from 4–8 months and clinical activity did not warrant further Phase III trials.

**Nab-paclitaxel**

Nab-paclitaxel is a colloidal suspension of 130 nm particles homogenized in human serum albumin bound to paclitaxel. Sparreboom et al demonstrated the pharmacokinetics of nab-paclitaxel and paclitaxel in humans and in animals models, and showed that the volumes of distribution were higher by 50% for nab-paclitaxel. Better bioavailability of nab-paclitaxel compared to serum-bound paclitaxel was noted in other studies as well. Desai et al demonstrated in nude mice bearing human xenograft tumors, that intratumoral accumulation, absorption, binding to the endothelial cells, and transportation were higher for nab-paclitaxel compared with paclitaxel.

The drug delivery of nab-paclitaxel is associated with the gp60 albumin receptor as well as secreted protein acidic
and rich in cysteine (SPARC) expressed in many cancer cells. SPARC has a high affinity to albumin; therefore, nab-paclitaxel has increased intratumoral concentration in cancer patients. SPARC is a calcium-binding protein, and is present on tumor cells and stromal fibroblasts, which play an important role in promoting epithelial-to-mesenchymal transition and invasion through matrix metalloproteinase expression. Overexpression of SPARC in the stroma is recognized to promote cancer cell invasion and metastasis. Infante et al showed that PC patients had worse prognoses with higher SPARC on stromal fibroblast. Since SPARC is a mechanism for nab-paclitaxel delivery, pancreatic tumors with higher expressions of SPARC were associated with improved survival for patients who received the combination of nab-paclitaxel and gemcitabine in early clinical trials. Current studies are evaluating if SPARC could be used as a biomarker for nab-paclitaxel-based chemotherapy.

**Nab-paclitaxel and gemcitabine in PC**

Chemotherapy resistance to common agents like gemcitabine is one of the reasons why PC cells become more aggressive and cause poor outcomes in these patients. PC cells stroma serves as a mechanical barrier and promotes tumor formation, progression, invasion, and metastasis. Alvarez et al demonstrated cancer stroma and tumor softening, mainly related to nab-paclitaxel and not gemcitabine. Von Hoff et al examined the molecular profile of different solid tumors from 91 patients to identify potential targets and resistance to the current chemotherapeutic agents, including combining gemcitabine with different agents and possible synergism. Frese et al demonstrated how cytidine deaminase, an enzyme involved in the metabolic deactivation of gemcitabine, could be inhibited by nab-paclitaxel. Preclinical data suggested that SPARC was overexpressed in pancreatic adenocarcinoma samples and the early work of Von Hoff used SPARC as a possible target for nab-paclitaxel. In the pilot Phase I/II study, a combination of nab-paclitaxel and gemcitabine was used in advanced PC patients. The results of the clinical efficacy data were promising. The median overall survival was 12.2 months (95% CI: 8.9–17.9 months), the median progression-free survival was 7.9 months (95% CI: 5.8–11.0 months), and the overall response rate was 46%. In the study, a PET scan was used to assess if metabolic responders do better than non-responders. The subset analysis showed that patients who had complete metabolic response had a median overall survival of 20.1 months versus 10.3 months in non-responders (P=0.01).

Zhang et al performed a similar study in 21 Chinese patients and had a median overall survival of 12.2 months (95% CI: 9.5–14.8 months) and an overall response rate of 28% in advanced PC patients. These promising results of early clinical trials led to the largest Phase III trial in advanced PC. It was a randomized study comparing gemcitabine and nab-paclitaxel to single agent gemcitabine in 861 untreated advanced PC patients. The study was conducted in 151 sites on three continents, including many in community practices in the US. The patients were distributed in a 1:1 ratio, with 431 in the combination arm and 430 in the standard gemcitabine arm. Patient demographics were well matched in both the experimental and control group as shown in Table 1. The median age of the study population was 63 with slightly more male predominance. The study included patients with a Karnofsky performance status (KPS) of 70–100. Therefore, the study included some patients who had a SWOG (Southwest Oncology Group) performance status of 2. The majority of patients had liver metastasis and up to 46% of patients had three or more sites of metastatic disease. Since the study required a normal bilirubin level, majority of patients had primary PC in the body and tail of the pancreas and about 43% had the primary location in the head of the pancreas. Biliary stents were reported in 19% of experimental and 16% of the standard arm, respectively.

Nab-paclitaxel was given at 125 mg/m² with gemcitabine at 1,000 mg/m² on days 1, 8, and 15, every 4 weeks. Gemcitabine was given weekly at 1,000 mg/m² for 7 weeks followed by 1 week of rest on the first cycle. In the subsequent
cycles, gemcitabine was given weekly on days 1, 8, and 15, every 4 weeks. The median overall survival was 8.5 versus 6.7 months (hazard ratio [HR]: 0.72, 95% CI: 0.62–0.84, \( P=0.001 \)), the median progression free survival was 5.5 versus 3.7 months (HR: 0.69, 95% CI: 0.58–0.82, \( P=0.001 \)), and 1-year survival was 35% versus 22%, all in favor of the combination of gemcitabine and nab-paclitaxel.\(^{40}\)

**Toxicity**

As shown by the MPACT study, the addition of nab-paclitaxel to gemcitabine in the treatment of patients with advance PC increases survival by 2 months. As noted with any doublet chemotherapy, nab-paclitaxel combined with gemcitabine increased the hematological toxicity profile compared to single agent gemcitabine. Bone marrow suppression was both dose dependent and dose limiting toxicity for the combination of gemcitabine and nab-paclitaxel. Severe neutropenia was noted in 38% of the combination arm as compared to 27% in the gemcitabine arm. However, febrile neutropenia was rare in both treatment arms (3% in doublet and 1% in gemcitabine). Use of growth factor was higher in the combination arm (26% versus 15%) than the standard arm. The main non-hematological toxicity was neuropathy associated with nab-paclitaxel and fatigue, which were more pronounced in the combination arm. Interestingly, most of the peripheral neuropathy was reversible, with grade 1 or less, 30 days after stopping nab-paclitaxel. Other common non-hematologic toxicity symptoms such as alopecia, mucositis, and alterations in taste sensation were compared to the gemcitabine group and are listed in Table 2. Overall, the combination arm was well tolerated and manageable in most advanced PC patients.

**Nab-paclitaxel in other cancers**

Taxanes have been recognized as a viable form of therapy for the treatment of breast cancer. Therefore, it was reasonable to evaluate nab-paclitaxel as an alternative to taxol in breast cancer models.\(^{41}\) Gradishar et al compared nab-paclitaxel with standard paclitaxel in 454 metastatic breast cancer patients.\(^{42}\) The overall response rate was 33% versus 19% and the median time-to-progression was 23 versus 16.9 weeks, respectively, favoring nab-paclitaxel. Similarly, Socinski et al reported the result of a Phase III trial comparing nab-paclitaxel with paclitaxel in combination with carboplatin in 1,152 advanced lung cancer patients.\(^{43}\) In this trial, nab-paclitaxel was given at 100 mg/m² on days 1, 8, and 15 of a 3-week cycle in combination with carboplatin in 1,152 advanced lung cancer patients.\(^{44}\) In this trial, nab-paclitaxel was given at 100 mg/m² on days 1, 8, and 15 of a 3-week cycle at the same dose and schedule of carboplatin. The overall response rate was 33% versus 25% and the median overall survival was 12.1 versus 11.2 months, respectively, favoring nab-paclitaxel. Nab-paclitaxel is currently approved in the treatment of both advanced breast and lung cancer patients.

**Discussion**

Advanced PC continues to be one of the most aggressive malignancies with limited treatment options. Gemcitabine has been the only treatment for decades. Although the addition of erlotinib statistically increased survival from 5.9 to 6.4 months when compared with gemcitabine,\(^{45}\) or other gemcitabine-based regimens. However, the regimen was found to increase hematologic toxicity and associated toxicity. The landscape of advanced PC changed when Conroy et al demonstrated that FOLFIRINOX, a (combination of 5-FU, oxaliplatin, and irinotecan) increased the median overall survival in 342 advanced PC patients from 6.4 to 11.1 months when compared with gemcitabine.\(^{46}\) However, the regimen was found to increase hematologic and gastrointestinal (GI) toxicity and has been restricted to the very fit, younger patient population with good performance status. A recent survey of practicing American oncologists showed that FOLFIRINOX is used in only about 20%–25% of advanced PC patients due to age and performance status.\(^{47}\) Therefore, the vast majority of pancreatic patients still receive single agent gemcitabine or other gemcitabine-based regimens.

### Table 2 Select non-hematologic adverse reactions reported in the MPACT trial

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Nab-paclitaxel + gemcitabine N=421</th>
<th>Gemcitabine N=402</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All grades N (%)</td>
<td>Grade 3 or higher N (%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>248 (59%)</td>
<td>77 (18%)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>171 (41%)</td>
<td>12 (3%)</td>
</tr>
<tr>
<td>Anemia</td>
<td>79 (19%)</td>
<td>29 (7%)</td>
</tr>
<tr>
<td>Mucositis</td>
<td>42 (10%)</td>
<td>6 (1%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>228 (54%)</td>
<td>27 (6%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>151 (36%)</td>
<td>25 (6%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>26 (44%)</td>
<td>26 (6%)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>212 (50%)</td>
<td>6 (1%)</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>227 (54%)</td>
<td>70 (17%)</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>68 (16%)</td>
<td>0</td>
</tr>
<tr>
<td>Anorexia</td>
<td>152 (36%)</td>
<td>23 (5%)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>47 (11%)</td>
<td>3 (1%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>44 (10%)</td>
<td>4 (1%)</td>
</tr>
</tbody>
</table>

**Abbreviation:** MPACT, Metastatic Pancreatic Adenocarcinoma Clinical Trial.
It is hard to make any definite conclusions when comparing two different Phase III studies like FOLFIRINOX and MPACT study. However, both modern studies had very similar control groups in terms of overall survival (6.8 months versus 6.7 months) and progression-free survival. In both studies, the demographic profiles for the experimental and control arms were very well balanced. Therefore, if we compare the absolute survival data, FOLFIRINOX had a superior clinical outcome with 11.1 months compared to 8.5 months in the nab-paclitaxel and gemcitabine combination, as well as an improved response rate (32% versus 23%). Therefore, FOLFIRINOX will remain as the standard option in young, fit patients with good performance status in advanced PC.

The MPACT study presented by Von Hoff demonstrated that nab-paclitaxel and gemcitabine regimen, improved OS of 861 PC patients from 6.7 months to 8.5 months when compared to single agent gemcitabine. The key difference in the eligibility criteria of the FOLFIRINOX and MPACT trials was that the MPACT study allowed elderly patients (age >75 years) and that performance status with KPS 70 was allowed in the study. Interestingly, the sub-set analysis of patients who had KPS 70–80 had similar overall survival benefits with KPS 90–100. The toxicity profile for both gemcitabine and nab-paclitaxel with FOLFIRINOX is similar; however, hematological toxicities and growth factor usage was higher in the FOLFIRINOX arm, while nab-paclitaxel plus gemcitabine demonstrated higher rates of neuropathy. Another practical difference in the two regimens is that the FOLFIRINOX regimen is given every 2 weeks and utilizes the 46-hour 5-FU infusion, while gemcitabine and nab-paclitaxel is given as a weekly infusion.

In conclusion, nab-paclitaxel in combination with gemcitabine has emerged as a new form of therapy for PC and will replaced single agent gemcitabine. It is anticipated that a detailed analysis of the molecular mechanism of action of nab-paclitaxel, especially in the presence of gemcitabine, will allow the better design of therapies against pancreatic adenocarcinoma. Clinical trials using gemcitabine and nab-paclitaxel are already starting to recruit patients to discover its benefit in locally advanced PC and in adjuvant settings. With lower hematological toxicity, this combination should be explored as a backbone in combining novel targeted therapies in the future.

**Disclosure**

Dr. Choi received honorarium from Celgene. No funding was received for this study. The other authors report no conflicts of interest in this work.

**References**


